Calming the (Cytokine) storm: Dimethyl fumarate as a therapeutic candidate for covid-19

[thumbnail of pharmaceuticals-14-00015.pdf]
pharmaceuticals-14-00015.pdf - Published Version (1MB) | Preview
Available under license: Creative Commons Attribution

Timpani, Cara ORCID: 0000-0003-4567-4319 and Rybalka, Emma ORCID: 0000-0002-4854-0036 (2021) Calming the (Cytokine) storm: Dimethyl fumarate as a therapeutic candidate for covid-19. Pharmaceuticals, 14 (1). pp. 1-15. ISSN 1424-8247 (In Press)


COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.3390/ph14010015
Official URL
Subjects Historical > FOR Classification > 0601 Biochemistry and Cell Biology
Historical > FOR Classification > 1109 Neurosciences
Current > Division/Research > Institute for Health and Sport
Keywords severe acute respiratory syndrome coronavirus type-2, SARS-CoV-2, COVID-19 pandemic, Dimethyl fumarate, DMF, approved drug, immunomodulatory properties, anti-oxidative properties, anti-inflammatory properties, hyperinflammation
Citations in Scopus 21 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login